mouse basic fgf (bfgf)  (PeproTech)

Journal: Cell reports

Article Title: Placenta-derived SOD3 deletion impairs maternal behavior via alterations in FGF/FGFR-prolactin signaling axis

doi: 10.1016/j.celrep.2024.114789

Figure Lengend Snippet: (A) Reactome pathway analysis of placental Sod3 f/f and Sod3 −/− dams. (B) Prl mRNA expression levels of 100 ng/mL recombinant fibroblast growth factor (FGF)1-, FGF2-, or FGF4-stimulated mouse primary pituitary cells with or without 10 μM FGF receptor (FGFR) inhibitors. BGJ398: FGFR1/2/3 inhibitor, PD16686: FGFR1 inhibitor, H3B-6527: FGFR4 inhibitor. N = 5; three technical replicates for each group; ** p < 0.01 vs. FGF1-control, †† p < 0.01 vs. FGF2-control, and ‡‡ p < 0.01 vs. FGF4-control. (C) Prl mRNA expression levels in recombinant FGF1-, FGF2-, or FGF4-stimulated primary pituitary cells from placental Sod3 f/f and Sod3 −/− dams on day 10 after delivery. (D) Phosphorylation levels of FGFR-induced signaling molecules in recombinant FGF1-, FGF2-, or FGF4-stimulated primary pituitary cells from placental Sod3 f/f and Sod3 −/− dams. N = 3 in each group; three biological and technical replicates for each group.

Article Snippet: Serum, plasma, and pituitary tissue levels of SOD3 (OKCD01107, Aviva System Biology), prolactin (ab100736, abcam), oxytocin (292–84401, Fujifilm Wako), estradiol (KGE014, R&D Systems), progesterone (CSB-E05104m, Cusabio), corticosterone (ab108821, abcam), dopamine (BA E–5300R, ImmuSmol), placental lactogen (LS-F28728–1, LifeSpan BioSciences), FGF1 (DY4686–05, R&D Systems), FGF2 (DY3139–05, R&D Systems), and FGF4 (ELM-FGF4–1, Ray Biotech) were determined using ELISA according to the manufacturer’s instructions.

Techniques: Expressing, Recombinant, Control

Journal: Cell reports

Article Title: Placenta-derived SOD3 deletion impairs maternal behavior via alterations in FGF/FGFR-prolactin signaling axis

doi: 10.1016/j.celrep.2024.114789

Figure Lengend Snippet: (A) Gene expression levels of FGFRs and FGFs of the pituitary gland in sedentary or trained, WT or KO dams. (B) FGFR2 and FGF1 protein expression levels in the pituitary gland from sedentary or trained, WT or KO dams. (C–E) Plasma levels of FGF1 (C), FGF2 (D), and FGF4 (E) in sedentary or trained, WT or KO dams. (F and H) Total 5-mC (F) and 5-hmC (H) of pituitary tissues in sedentary or trained, WT or KO dams. (G and I) Relative DNA methylation levels (G) and 5-hmC abundance (I) at the promoter of Fgfr/Fgf genes in the pituitary gland from sedentary or trained, WT or KO dams. (J) Gene expression levels of Tet and Idh of the pituitary gland in sedentary or trained, WT or KO dams. (K–M) Levels of α-ketoglutarate (αKG) (K) and enzymatic activity of IDH (L) and TET (M) in the pituitary glands of sedentary or trained, WT or KO dams. N = 5 in each group; three technical replicates for each group. For (B), three biological replicates for each group. * p < 0.05 and ** p < 0.01.

Article Snippet: Serum, plasma, and pituitary tissue levels of SOD3 (OKCD01107, Aviva System Biology), prolactin (ab100736, abcam), oxytocin (292–84401, Fujifilm Wako), estradiol (KGE014, R&D Systems), progesterone (CSB-E05104m, Cusabio), corticosterone (ab108821, abcam), dopamine (BA E–5300R, ImmuSmol), placental lactogen (LS-F28728–1, LifeSpan BioSciences), FGF1 (DY4686–05, R&D Systems), FGF2 (DY3139–05, R&D Systems), and FGF4 (ELM-FGF4–1, Ray Biotech) were determined using ELISA according to the manufacturer’s instructions.

Techniques: Expressing, DNA Methylation Assay, Activity Assay

Journal: Cell reports

Article Title: Placenta-derived SOD3 deletion impairs maternal behavior via alterations in FGF/FGFR-prolactin signaling axis

doi: 10.1016/j.celrep.2024.114789

Figure Lengend Snippet:

Article Snippet: Serum, plasma, and pituitary tissue levels of SOD3 (OKCD01107, Aviva System Biology), prolactin (ab100736, abcam), oxytocin (292–84401, Fujifilm Wako), estradiol (KGE014, R&D Systems), progesterone (CSB-E05104m, Cusabio), corticosterone (ab108821, abcam), dopamine (BA E–5300R, ImmuSmol), placental lactogen (LS-F28728–1, LifeSpan BioSciences), FGF1 (DY4686–05, R&D Systems), FGF2 (DY3139–05, R&D Systems), and FGF4 (ELM-FGF4–1, Ray Biotech) were determined using ELISA according to the manufacturer’s instructions.

Techniques: Recombinant, Enzyme-linked Immunosorbent Assay, Catecholamine ELISA, Sandwich ELISA, Dehydrogenase Assay, Activity Assay, Software

Journal: Cell reports

Article Title: Placenta-derived SOD3 deletion impairs maternal behavior via alterations in FGF/FGFR-prolactin signaling axis

doi: 10.1016/j.celrep.2024.114789

Figure Lengend Snippet:

Article Snippet: Mouse FGF basic/FGF2/bFGF DuoSet ELISA , R&D Systems , DY3139-05.

Techniques: Recombinant, Enzyme-linked Immunosorbent Assay, Catecholamine ELISA, Clinical Proteomics, Sandwich ELISA, Dehydrogenase Assay, Activity Assay, Software

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Development and characterization of a novel injectable thyroid extracellular matrix hydrogel for enhanced thyroid tissue engineering applications

doi: 10.3389/fbioe.2024.1481295

Figure Lengend Snippet: Structural, Mechanical, and Growth Factor Characterization of Thyroid Extracellular Matrix (TEM) Hydrogels. (A) SEM images of type I collagen hydrogel, 10 mg/mL TEM hydrogel, and 20 mg/mL TEM hydrogel. (B) Elastic modulus of native thyroid tissue, type I collagen hydrogel, 10 mg/mL TEM hydrogel, and 20 mg/mL TEM hydrogel. (C) Toughness of native thyroid tissue, type I collagen hydrogel, 10 mg/mL TEM hydrogel, and 20 mg/mL TEM hydrogel. (D) Concentrations of growth factors (VEGF, TGF-β, HGF, FGF, EGF, and PDGF) in native thyroid tissue, 10 mg/mL TEM hydrogel, and 20 mg/mL TEM hydrogel. All data represent means ± SD. (n = 6; ** p < .01 vs. native thyroid, and p < .01 vs. 10 mg/mL TEM hydrogel).

Article Snippet: Specific ELISA kits were used to detect the content of growth factors, including VEGF (R&D Systems, RRV00), TGF-β (R&D Systems, RTB100B), HGF (R&D Systems, MHG00), FGF (R&D Systems, MFB00), EGF (R&D Systems, DY3214), and PDGF (R&D Systems, MBB00).

Techniques:

Journal: Journal of Cardiovascular Development and Disease

Article Title: FGFR4 Is Required for Concentric Growth of Cardiac Myocytes during Physiologic Cardiac Hypertrophy

doi: 10.3390/jcdd11100320

Figure Lengend Snippet: FGFR4 inhibition abrogates cardiac myocyte hypertrophy induced by serum from fed pythons. Neonatal rat ventricular myocytes (NRVMs) were treated with media containing either vehicle, FGF2 (25 ng/mL), FGF23 (25 ng/mL), or serum from fasted or fed snakes (diluted to 2% of the total media volume), without or in combination with a small molecule inhibitor of FGFR4 (iFGFR4; BLU9931, 10 ng/mL), for 48 h. Compared to vehicle-treated NRVMs (Ctrl) or to NRVMs treated with serum from fasted pythons, serum collected from pythons twelve hours post-feeding (Python 12HPF; #### p < 0.0001) and three days post-feeding (Python 3DPF; #### p < 0.0001) induced a significant increase in myocyte area. When co-treated with iFGFR4 (textured bars), both Python 12HPF (**** p < 0.0001) and Python 3DPF (*** p = 0.0003) did not induce a significant increase in NRVM area when compared to the same treatment without iFGFR4. Python 12HPF ( $$$ p = 0.0003)- and Python 3DPF ( $$ p = 0.0016)-treated NRVMs had significantly increased myocyte area when compared to Python Fasted serum treatments. Treatment with recombinant FGF23 significantly increased myocyte area compared to Ctrl ( #### p < 0.0001), fasted python serum treatments ( $$$$ p < 0.0001), and FGF23 + iFGFR4 treatment (**** p < 0.0001) NRVMs. Treatment with recombinant FGF2 protein served as a positive control for hypertrophy ( ## p = 0.003). Treatment with serum from fasted and two-days-post-feeding water snakes (Water Snake Fasted, Water Snake 2DPF) served as negative controls Each individual color corresponds with the treatment indicated below the bars. # = versus Ctrl; * = versus same treatment + iFGFR4; $ = versus Python Fasted; 150 cells per condition; n = 3–4 independent isolations of NRVMs. All values are shown as mean ± SD.

Article Snippet: We used recombinant murine FGF2 (3139-FB) and FGF23 (2629-FG/CF) proteins from R&D Systems.

Techniques: Inhibition, Recombinant, Positive Control

Journal: Journal of Cardiovascular Development and Disease

Article Title: FGFR4 Is Required for Concentric Growth of Cardiac Myocytes during Physiologic Cardiac Hypertrophy

doi: 10.3390/jcdd11100320

Figure Lengend Snippet: Mouse primer sequences. The following oligonucleotides shown in 5′ to 3′ orientation were used as primers in quantitative real-time PCR analyses.

Article Snippet: We used recombinant murine FGF2 (3139-FB) and FGF23 (2629-FG/CF) proteins from R&D Systems.

Techniques: Real-time Polymerase Chain Reaction, Sequencing

Journal: Journal of Cardiovascular Development and Disease

Article Title: FGFR4 Is Required for Concentric Growth of Cardiac Myocytes during Physiologic Cardiac Hypertrophy

doi: 10.3390/jcdd11100320

Figure Lengend Snippet: Serum FGF23 levels are elevated in mice during late pregnancy. Wild-type and global FGFR4 knockout (FGFR4 −/− ) mice were investigated during late pregnancy (LP; 18 days post-mating) and compared to non-pregnant virgin littermates (NP). Serum FGF23 concentrations were measured via ELISA. Both ( A ) total FGF23 and ( B ) intact FGF23 were significantly elevated in the serum of wild-type (total **** p < 0.0001; intact ** p = 0.0014) and FGFR4 −/− mice (total **** p < 0.0001; intact **** p < 0.0001) when compared to their respective NP controls (n = 8–12 mice per genotype and timepoint). FGFR4 −/− LP mice exhibit significantly higher intact FGF23 compared to wild-type LP mice (** p = 0.0055). ( C ) The ratios of intact FGF23 over total FGF23 show no significant differences between groups (n = 8–12 mice per genotype and timepoint). ( D ) Cardiac tissue from LP mice showed significant decreases in Klotho expression in wild-type mice (* p = 0.0398) compared to wild-type NP mice, but there were no significant differences between NP and LP in FGFR4 −/− mice (n = 4–6 mice per genotype and timepoint). Cardiac tissue from wild-type mice in LP showed a significant decline in Fgfr1 mRNA levels (** p = 0.0026), while FGFR4 −/− mice had no significant change in expression when compared to their respective NP control mice (n = 6–9 mice per genotype and timepoint). Fgfr4 expression in cardiac tissue from wild-type mice in LP remained unaltered, compared to wild-type mice in LP (n = 7–8 mice per genotype and timepoint). RTqPCR analysis of tissue was conducted using Gapdh as a housekeeping gene. All values are shown as ±SD.

Article Snippet: We used recombinant murine FGF2 (3139-FB) and FGF23 (2629-FG/CF) proteins from R&D Systems.

Techniques: Knock-Out, Enzyme-linked Immunosorbent Assay, Expressing, Control

Journal: Journal of Cardiovascular Development and Disease

Article Title: FGFR4 Is Required for Concentric Growth of Cardiac Myocytes during Physiologic Cardiac Hypertrophy

doi: 10.3390/jcdd11100320

Figure Lengend Snippet: FGF23 is expressed in the heart during late pregnancy in mice. ( A ) In wild-type mice during late pregnancy (LP; 18 days post-mating), Fgf23 mRNA levels were not altered in bone or liver tissue compared to non-pregnancy (NP) (n = 5–6 mice per timepoint). ( B ) Cardiac tissue from LP mice showed significant increases in Fgf23 expression in both wild-type (* p = 0.0213) and FGFR4 knockout (FGFR4 −/− ) (* p = 0.0246) mice when compared to respective NP controls (n = 4–8 mice per genotype and timepoint). ( C ) In cardiac tissue of wild-type mice, no differences in the mRNA levels of the FGF23 regulatory genes Galnt3 , Furin , or Fam20c were observed between NP and LP (n = 7–8 mice per timepoint). ( D ) Bone tissue from wild-type mice showed no differences in mRNA levels of Galnt3 , Furin , or Fam20c (n = 5–6 mice per timepoint) in NP versus LP. RTqPCR analysis of tissue was conducted using Gapdh as a housekeeping gene. All values are shown as mean ± SD.

Article Snippet: We used recombinant murine FGF2 (3139-FB) and FGF23 (2629-FG/CF) proteins from R&D Systems.

Techniques: Expressing, Knock-Out

Journal: Journal of Cardiovascular Development and Disease

Article Title: FGFR4 Is Required for Concentric Growth of Cardiac Myocytes during Physiologic Cardiac Hypertrophy

doi: 10.3390/jcdd11100320

Figure Lengend Snippet: Pregnant mice have increased serum phosphorus and calcium despite FGF23 elevations. ( A ) Serum phosphorus was significantly elevated during late pregnancy (LP; 18 days post-mating) in wild-type mice (* p = 0.0196; n = 14–19 mice per timepoint) and FGFR4 knockout (FGFR4 −/− ) mice (**** p < 0.0001; n = 8–11) when compared to non-pregnant (NP) mice. FGFR4 −/− LP mice have significantly higher serum phosphorus compared to wild-type LP mice (** p = 0.0093; n = 8–14). ( B ) Serum calcium was also significantly elevated in pregnant wild-type (*** p = 0.0001; n = 14–19) and FGFR4 −/− mice (** p = 0.0026; n = 9–12), compared to NP controls. FGFR4 −/− LP mice have significantly higher serum calcium compared to wild-type LP mice (* p = 0.0364; n = 9–14). Renal tissue from wild-type mice in LP exhibited no alterations in the mRNA levels of ( C ) sodium-dependent phosphate transporters Slc34a1 and Slc34a3 or of ( D ) Klotho , Fgfr1 , or Fgfr4 (n = 8 mice per timepoint). RTqPCR analysis of tissue was conducted using Gapdh as a housekeeping gene. All values are shown as mean ± SD.

Article Snippet: We used recombinant murine FGF2 (3139-FB) and FGF23 (2629-FG/CF) proteins from R&D Systems.

Techniques: Knock-Out

Journal: Journal of Cardiovascular Development and Disease

Article Title: FGFR4 Is Required for Concentric Growth of Cardiac Myocytes during Physiologic Cardiac Hypertrophy

doi: 10.3390/jcdd11100320

Figure Lengend Snippet: FGFR4 inhibition abrogates cardiac myocyte hypertrophy induced by serum from fed pythons. Neonatal rat ventricular myocytes (NRVMs) were treated with media containing either vehicle, FGF2 (25 ng/mL), FGF23 (25 ng/mL), or serum from fasted or fed snakes (diluted to 2% of the total media volume), without or in combination with a small molecule inhibitor of FGFR4 (iFGFR4; BLU9931, 10 ng/mL), for 48 h. Compared to vehicle-treated NRVMs (Ctrl) or to NRVMs treated with serum from fasted pythons, serum collected from pythons twelve hours post-feeding (Python 12HPF; #### p < 0.0001) and three days post-feeding (Python 3DPF; #### p < 0.0001) induced a significant increase in myocyte area. When co-treated with iFGFR4 (textured bars), both Python 12HPF (**** p < 0.0001) and Python 3DPF (*** p = 0.0003) did not induce a significant increase in NRVM area when compared to the same treatment without iFGFR4. Python 12HPF ( $$$ p = 0.0003)- and Python 3DPF ( $$ p = 0.0016)-treated NRVMs had significantly increased myocyte area when compared to Python Fasted serum treatments. Treatment with recombinant FGF23 significantly increased myocyte area compared to Ctrl ( #### p < 0.0001), fasted python serum treatments ( $$$$ p < 0.0001), and FGF23 + iFGFR4 treatment (**** p < 0.0001) NRVMs. Treatment with recombinant FGF2 protein served as a positive control for hypertrophy ( ## p = 0.003). Treatment with serum from fasted and two-days-post-feeding water snakes (Water Snake Fasted, Water Snake 2DPF) served as negative controls Each individual color corresponds with the treatment indicated below the bars. # = versus Ctrl; * = versus same treatment + iFGFR4; $ = versus Python Fasted; 150 cells per condition; n = 3–4 independent isolations of NRVMs. All values are shown as mean ± SD.

Article Snippet: We used recombinant murine FGF2 (3139-FB) and FGF23 (2629-FG/CF) proteins from R&D Systems.

Techniques: Inhibition, Recombinant, Positive Control